Letermovir

Letermovir (INN; trade name Prevymis) is an antiviral drug for the treatment of cytomegalovirus (CMV) infections. It has been tested in CMV infected patients with allogeneic stem cell transplants and may also be useful for other patients with a compromised immune system such as those with organ transplants or HIV infections.[1] The drug was developed by Merck & Co., Inc as investigative compound MK-8228.[2]

Letermovir

Clinical data
Trade names	Prevymis
Other names	AIC246; MK-8228
AHFS/Drugs.com	Monograph
MedlinePlus	a618006
License data	US DailyMed: Letermovir
Pregnancy category	AU: B3
Routes of administration	By mouth, intravenous
ATC code	J05AX18 (WHO)
Legal status
Legal status	AU: S4 (Prescription only) US: ℞-only EU: Rx-only
Identifiers
IUPAC name {(4S)-8-Fluoro-2-[4-(3-methoxyphenyl)-1-piperazinyl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-3,4-dihydro-4-quinazolinyl}acetic acid
CAS Number	917389-32-3
PubChem CID	45138674
DrugBank	DB12070
ChemSpider	26352849
UNII	1H09Y5WO1F
KEGG	D10801
ChEMBL	ChEMBL1241951
CompTox Dashboard (EPA)	DTXSID40238683
ECHA InfoCard	100.232.644
Chemical and physical data
Formula	C29H28F4N4O4
Molar mass	572.561 g·mol^−1
3D model (JSmol)	Interactive image
SMILES COC1=C(C=C(C=C1)C(F)(F)F)N2[C@H](C3=C(C(=CC=C3)F)N=C2N4CCN(CC4)C5=CC(=CC=C5)OC)CC(=O)O
InChI InChI=1S/C29H28F4N4O4/c1-40-20-6-3-5-19(16-20)35-11-13-36(14-12-35)28-34-27-21(7-4-8-22(27)30)23(17-26(38)39)37(28)24-15-18(29(31,32)33)9-10-25(24)41-2/h3-10,15-16,23H,11-14,17H2,1-2H3,(H,38,39)/t23-/m0/s1 Key:FWYSMLBETOMXAG-QHCPKHFHSA-N

The drug was granted fast track status by the US Food and Drug Administration (FDA) and orphan drug status by the European Medicines Agency.[1] In the United States, it is approved for prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic hematopoietic stem cell transplant.[3]

The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.[4]

References

1. "Neues Virostatikum Letermovir" (in German). Deutsche Apothekerzeitung. 2011-08-29.
2. Masangkay, Estel Grace (July 29, 2014). "Merck Kicks Off Phase 3 Study Of CMV Drug Letermovir". Retrieved 8 Oct 2014.
3. "FDA Approves Letermovir for CMV Prophylaxis Post-Transplantation". onclive.com. November 9, 2017.
4. New Drug Therapy Approvals 2017 (PDF). U.S. Food and Drug Administration (FDA) (Report). January 2018. Retrieved 16 September 2020.

External links

• "Letermovir". Drug Information Portal. U.S. National Library of Medicine.
• "Letermovir Injection". MedlinePlus.